Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

Blood (2023) 142 (Supplement 2): LBA-5.

https://doi.org/10.1182/blood-2023-192042

Published: 2023

Journal Articles

Multiomic Single-Cell Sequencing May Distinguish BCR-ABL-Mutated Acute Myeloid Leukemia (AML) from Blast Crisis Chronic Myelogenous Leukemia (BC-CML)

Vanessa E. Kennedy, Cheryl A C Peretz, Andrew Koh, Elaine Tran, Dalia Dhingra, Saurabh Gulati, Adam Sciambi, Olga Sala-Torra, Lan Beppu, Aaron C. Logan, Alexander Perl, Wendy Stock, Geoffrey L Uy, Ann-Kathrin Eisfeld, Jerald P. Radich, Catherine C. Smith

Blood (2023) 142 (Supplement 1): 4334.

https://doi.org/10.1182/blood-2023-182454

Published: 2023

Journal Articles

Patient-Reported Outcome Measures Associated with Overall Survival and Acute Care Use in Patients with Newly Diagnosed Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Acute Lymphoblastic Leukemia

Seiichi Villalona, Xin Wang, Peter Gabriel, Abigail Doucette, Shannon R McCurdy, Alexander Perl, Selina M Luger, Noelle V. Frey, Ximena Jordan Bruno, Elizabeth O Hexner, Daria V Babushok, David L. Porter, Alison W Loren, Keith W Pratz, Catherine Lai

Blood (2023) 142 (Supplement 1): 5183.

https://doi.org/10.1182/blood-2023-178247

Published: 2023

Journal Articles

Quantum-First (Q-F): Clinical Bridging Study for FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3 -ITD) Companion Diagnostic Development

Jaime E Rohrbach, Ken C N Chang, Maha Karnoub, Li Liu, Yasser Mostafa Kamel, Shirin Khambata-Ford, Shawn Rivera, Jelveh Lameh, Ekaterina Rudenko, Jordan Thornes, Sarah Todt, Jason Gerhold, Ying Huang, Jeffrey E Miller, Alexander Perl, Mark J. Levis, Kazumi Ito

Blood (2023) 142 (Supplement 1): 4260.

https://doi.org/10.1182/blood-2023-186658

Published: 2023

Journal Articles

Quantum-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3 -ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed through Induction (IND) and Consolidation (CONS) Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (nd) FLT3 -ITD+ AML Patients (pts)

Blood (2023) 142 (Supplement 1): 832.

https://doi.org/10.1182/blood-2023-186785

Published: 2023

Journal Articles

Frail and Pre-Frail Older Adults with Acute Myeloid Leukemia Have Inferior Survival Due to Higher Rates of Disease-Related Deaths

Ashley D Hadjis, Griffin W White, Christopher Catania, Noelle V. Frey, Saar Gill, Elizabeth O Hexner, Ximena Jordan Bruno, Catherine Lai, Andrew H Matthews, Mary Ellen Martin, Daria V Babushok, Alexander Perl, David L. Porter, Alison W Loren, Keith W Pratz, Selina M Luger, Shannon R McCurdy

Blood (2023) 142 (Supplement 1): 376.

https://doi.org/10.1182/blood-2023-188978

Published: 2023

Journal Articles

Kinetics of Complete Remission (CR) and CR Duration and Its Impact on Overall Survival (OS) and Event-Free Survival (EFS) in Quantum-First

Pau Montesinos, Alexander Perl, Mikkael A. Sekeres, Li Liu, Yasser Mostafa Kamel, Karima Imadalou, Richard F Schlenk, Harry P. Erba, Hervé Dombret

Blood (2023) 142 (Supplement 1): 4254.

https://doi.org/10.1182/blood-2023-187286

Published: 2023

Journal Articles

Post-Hoc Analysis of Measurable Residual Disease from BMT-CTN 1506/Morpho: FLT3-ITD Variant Allele Frequency and Survival Are Highly Correlated

Blood (2023) 142 (Supplement 1): 973.

https://doi.org/10.1182/blood-2023-177929

Published: 2023

Journal Articles

Quantum-First: Safety By Treatment Phase and By Age in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3 -ITD) Positive Acute Myeloid Leukemia (AML)

Harry P. Erba, Herve Dombret, Alexander Perl, Tsvetomir Mitov, Li Liu, Yasser Mostafa Kamel, Karima Imadalou, Youngsook Choi, Mark J. Levis, Richard F Schlenk

Blood (2023) 142 (Supplement 1): 972.

https://doi.org/10.1182/blood-2023-186206

Published: 2023

Journal Articles

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study

Blood (2023) 142 (Supplement 1): 2907.

https://doi.org/10.1182/blood-2023-189762

Published: 2023

Journal Articles

Evolving Racial/Ethnic Disparities in AML Survival in the Novel Therapy Era: Real-World Evidence of Improved Survival in Older Patients with the Largest Improvement in Non-Hispanic Black Patients

Blood (2023) 142 (Supplement 1): 955.

https://doi.org/10.1182/blood-2023-180185

Published: 2023

Journal Articles

Cytokine Release Syndrome Results in Reduced AML Killing By CD123 CAR T Cells

Blood (2023) 142 (Supplement 1): 217.

https://doi.org/10.1182/blood-2023-182104

Published: 2023

Journal Articles

Hypomethylating Agents Are Associated with High Rates of Hematologic Toxicity in Patients with Secondary MDS/AML That Develops after Acquired Aplastic Anemia

Matthew P Connor, Neeharika Prathapa, Noelle V. Frey, Saar Gill, Elizabeth O Hexner, Ximena Jordan Bruno, Catherine Lai, Alison W Loren, Selina M Luger, Andrew H Matthews, Shannon R McCurdy, Alexander Perl, David L. Porter, Arlene Zeringue, Joseph H. Oved, Timothy S Olson, Keith W Pratz, Daria V Babushok

Blood (2023) 142 (Supplement 1): 2720.

https://doi.org/10.1182/blood-2023-179383

Published: 2023

Journal Articles

Comparing Cairo Bishop and Howard Criteria for Identifying Clinically Meaningful Tumor Lysis Syndrome Among Acute Myeloid Leukemia Patients Treated with Venetoclax and Hypomethylating Agents: A Single Center Experience

Blood (2023) 142 (Supplement 1): 5095.

https://doi.org/10.1182/blood-2023-186978

Published: 2023

Journal Articles

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R. Wilson, Marina Konopleva, Arthur E. Frankel, Vikas Gupta, Ruben Mesa, Matthew Ulrickson, Edward Gorak, Sumeet Bhatia, Tulin Budak-Alpdogan, James Mason, Maria Teresa Garcia-Romero, Norma Lopez-Santiago, Gabriela Cesarman-Maus, Pankit Vachhani, Sangmin Lee, Vijaya Raj Bhatt, William Blum, Roland B. Walter, Dale Bixby, Ivana Gojo, Madeleine Duvic, Raajit K. Rampal, Marcos de Lima, James Foran, Amir T. Fathi, Aric Cameron Hall, Meagan A. Jacoby, Jeffrey Lancet, Gabriel Mannis, Anthony S. Stein, Alice Mims, David Rizzieri, Rebecca Olin, Alexander Perl, Gary Schiller, Paul Shami, Richard M. Stone, Stephen Strickland, Matthew J. Wieduwilt, Naval Daver, Farhad Ravandi, Sumithira Vasu, Monica Guzman, Gail J. Roboz, Joseph Khoury, Muzaffar Qazilbash, Phyu P. Aung, Branko Cuglievan, Yazan Madanat, Mohamed A. Kharfan-Dabaja, Anna Pawlowska, Justin Taylor, Martin Tallman, Prajwal Dhakal, Andrew A. Lane

Blood (2023) 141 (6): 567–578.

https://doi.org/10.1182/blood.2022017865

Published: 2023

Journal Articles

Multi-Omic Single-Cell Sequencing Reveals Genetic and Immunophenotypic Clonal Selection in Patients With FLT3-Mutated AML Treated With Gilteritinib/Venetoclax

Vanessa E. Kennedy, Cheryl Peretz, Paul Lee, Brenda Chyla, Yan Sun, Monique Dail, Jason Hill, Elaine Tran, Andrew Koh, Jessica K. Altman, Naval Daver, Mark J. Levis, James McCloskey, Alexander Perl, Catherine Smith

Blood (2022) 140 (Supplement 1): 2244–2246.

https://doi.org/10.1182/blood-2022-160304

Published: 2022

Journal Articles

A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL): Results of the ECOG-ACRIN EA9131 Trial

Anand P. Jillella, Sandra J. Lee, Jessica K. Altman, Selina M. Luger, Martin S. Tallman, James M. Foran, Lisa Y. Law, Locke J. Bryan, Abdallah Abou Zahr, Kebede Begna, Alexander Perl, Joseph Vadakara, Federico Sanchez, Raymond C. Bergan, Michael J. Fisch, Ruth C. Carlos, Lynne I. Wagner, Mark R. Litzow, Vamsi K. Kota

Blood (2022) 140 (Supplement 1): 1011–1013.

https://doi.org/10.1182/blood-2022-163436

Published: 2022

Journal Articles

Quantum-First Trial: FLT3 -ITD-Specific MRD Clearance Is Associated with Improved Overall Survival

Blood (2022) 140 (Supplement 1): 546–548.

https://doi.org/10.1182/blood-2022-162739

Published: 2022

Journal Articles

Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML

Amy Sexauer, Alexander Perl, Xiaochuan Yang, Michael Borowitz, Christopher Gocke, Trivikram Rajkhowa, Christian Thiede, Mark Frattini, Grant E. Nybakken, Keith Pratz, Judith Karp, B. Douglas Smith, Mark Levis

Blood (2012) 120 (20): 4205–4214.

https://doi.org/10.1182/blood-2012-01-402545

Published: 2012

Includes: Supplemental data

Journal Articles

A Feasibility Study of Rapamycin with Hyper-CVAD Chemotherapy in Adults with Acute Lymphoblastic Leukemia (ALL) and Other Aggressive Lymphoid Malignancies and Evaluation of mTOR Signaling Using Phosphoflow

Emma C Scott, MD, Alexander Perl, MD, Selina M. Luger, MD, Martin Carroll, MD, Margaret Kasner, MD

Blood (2011) 118 (21): 4245.

https://doi.org/10.1182/blood.V118.21.4245.4245

Published: 2011

NARROW

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

Multiomic Single-Cell Sequencing May Distinguish BCR-ABL-Mutated Acute Myeloid Leukemia (AML) from Blast Crisis Chronic Myelogenous Leukemia (BC-CML)

Patient-Reported Outcome Measures Associated with Overall Survival and Acute Care Use in Patients with Newly Diagnosed Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Acute Lymphoblastic Leukemia

Quantum-First (Q-F): Clinical Bridging Study for FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3 -ITD) Companion Diagnostic Development

Frail and Pre-Frail Older Adults with Acute Myeloid Leukemia Have Inferior Survival Due to Higher Rates of Disease-Related Deaths

Kinetics of Complete Remission (CR) and CR Duration and Its Impact on Overall Survival (OS) and Event-Free Survival (EFS) in Quantum-First

Post-Hoc Analysis of Measurable Residual Disease from BMT-CTN 1506/Morpho: FLT3-ITD Variant Allele Frequency and Survival Are Highly Correlated

Quantum-First: Safety By Treatment Phase and By Age in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3 -ITD) Positive Acute Myeloid Leukemia (AML)

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study

Evolving Racial/Ethnic Disparities in AML Survival in the Novel Therapy Era: Real-World Evidence of Improved Survival in Older Patients with the Largest Improvement in Non-Hispanic Black Patients

Cytokine Release Syndrome Results in Reduced AML Killing By CD123 CAR T Cells

Hypomethylating Agents Are Associated with High Rates of Hematologic Toxicity in Patients with Secondary MDS/AML That Develops after Acquired Aplastic Anemia

Comparing Cairo Bishop and Howard Criteria for Identifying Clinically Meaningful Tumor Lysis Syndrome Among Acute Myeloid Leukemia Patients Treated with Venetoclax and Hypomethylating Agents: A Single Center Experience

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Multi-Omic Single-Cell Sequencing Reveals Genetic and Immunophenotypic Clonal Selection in Patients With FLT3-Mutated AML Treated With Gilteritinib/Venetoclax

A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL): Results of the ECOG-ACRIN EA9131 Trial

Quantum-First Trial: FLT3 -ITD-Specific MRD Clearance Is Associated with Improved Overall Survival

Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML

A Feasibility Study of Rapamycin with Hyper-CVAD Chemotherapy in Adults with Acute Lymphoblastic Leukemia (ALL) and Other Aggressive Lymphoid Malignancies and Evaluation of mTOR Signaling Using Phosphoflow

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only